Business Context and Reporting Period
This Form 6-K filing by Celsus Therapeutics PLC (note: metadata lists Akari Therapeutics, but the document explicitly names Celsus Therapeutics) is dated February 11, 2014. The report discloses corporate actions taken by the Board of Directors on February 5, 2014, regarding executive and director compensation for the fiscal year ended December 31, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on compensation awards.
- CEO Bonus: $115,500 (33% of annual base salary).
- CFO Bonus: $50,000 (25% of annual base salary).
- CEO Stock Option Grant: 120,000 ordinary shares.
- CFO Stock Option Grant: 40,000 ordinary shares.
- Director Stock Option Grants: Ranging from 20,000 to 40,000 shares per director depending on committee roles.
Material Changes
The filing does not report material changes in financial performance or operations compared to prior periods. The primary change disclosed is the approval of specific cash bonuses and equity grants for the 2013 fiscal year.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. It is a routine disclosure of compensation decisions.
Unusual Items: None reported. The compensation structure follows the Company's 2007 Share Option Plan.
Key Facts for Investor Verification
- Verify the total cash outflow for executive bonuses ($165,500) and its impact on the company's cash position.
- Confirm the vesting schedule for the granted options, which is set for May 31, 2014, contingent on continued employment or directorship.
- Check the fair market value of the shares on the grant date to determine the exercise price for the new options.
- Review the total number of shares outstanding to assess the dilution impact of the 120,000 CEO shares, 40,000 CFO shares, and approximately 260,000 director shares granted.